Clinical Trials Regulation (536/2014)

The Clinical Trials Regulation (Regulation (EU) 536/2014) establishes a harmonised framework for the authorisation, conduct, and transparency of clinical trials in the European Union. Replacing Directive 2001/20/EC, the Regulation entered into application on 31 January 2022 after repeated delays in the development of the EU clinical trials portal and database. The Regulation aims to simplify the regulatory landscape, enhance patient safety, promote the EU’s competitiveness in clinical research, and increase transparency through mandatory public registration and results disclosure.

The Need for Reform

The Clinical Trials Directive (2001/20/EC) was criticised for creating divergent regulatory requirements across Member States, leading to increased costs, delays in trial initiation, and a significant reduction in the number of clinical trials conducted in the EU. The Directive’s transposition varied considerably, with differences in timelines, documentation requirements, insurance obligations, and definitions of substantial amendments. Academic and non-commercial sponsors were disproportionately affected by the administrative burden.

The Regulation addresses these problems by establishing a single, streamlined authorisation procedure through a centralised EU portal managed by the European Medicines Agency (EMA).

Streamlined Authorisation Procedure

The Regulation introduces a two-part authorisation process: the application is submitted through the Clinical Trials Information System (CTIS), a single EU portal and database. Part I of the application (covering scientific and medicinal product information) is assessed jointly by all Member States concerned, with a reporting Member State (RMS) coordinating the assessment. Part II (covering national ethical and legal requirements) is assessed by each Member State individually.

The RMS must validate the application within 10 days and assess Part I within 45 days, extendable by a further 50 days for clinical trials involving advanced therapy medicinal products or where additional information is required. Each Member State assesses Part II within the same timeline. The overall timeline from submission to authorisation is a maximum of 60 days (Part I) plus 45 days (Member States for Part II) — substantially shorter than the previous system where each Member State conducted separate assessments.

Single Member State assessment is available for trials conducted in only one Member State. The coordinated assessment for multi-state trials reduces duplication and inconsistency, as Member States must consider the assessment of the RMS and may only raise objections on grounds of justified divergence from national ethical standards.

CTIS Portal and Database

CTIS, developed by the EMA, serves as the single entry point for clinical trial applications, authorisations, and results reporting. The system provides public access to information about clinical trials conducted in the EU and the European Economic Area. CTIS replaces the previous fragmented registration and reporting requirements across the EU Clinical Trials Register and national registries.

CTIS operational from 31 January 2022, with a transitional period ending 31 January 2025, after which all clinical trials must comply with the Regulation. The system processes over 3,000 trial applications annually, facilitating the start-up of multinational trials and reducing administrative costs.

Ethics Review

The Regulation preserves the role of ethics committees in each Member State, recognising ethical review as a fundamental safeguard for the rights, safety, dignity, and well-being of trial participants (Article 4). Ethics committees assess Part II of the application, covering: informed consent procedures; suitability of investigators; compliance with data protection requirements; arrangements for compensation and insurance; and participant recruitment.

The Regulation does not harmonise ethics committee structures or procedures across Member States, respecting national constitutional traditions and ethical frameworks. However, the timeline for ethics review is integrated into the overall authorisation procedure.

Informed Consent

Articles 28 through 33 set out detailed requirements for informed consent. The general rule is that informed consent must be given freely in writing, dated and signed, after receiving information about the nature, significance, implications, and risks of the trial. Specific provisions address consent for minors (Article 32) and incapacitated adults (Article 31).

For incapacitated adults, the Regulation requires that: the incapacity is inherent to the condition being studied; the trial cannot be conducted with capable adults; the participant has received information according to their capacity; explicit consent has been obtained from a legal representative; and no objections have been raised by the participant.

Emergency research (Article 35) permits inclusion without prior consent where: immediate life-threatening or severely debilitating condition; no prior consent possible; the trial cannot be conducted without emergency enrolment; and consent is sought as soon as possible.

Transparency and Results Reporting

The Regulation establishes comprehensive transparency obligations. Article 36 requires sponsors to submit a summary of results to CTIS within one year of the trial’s end (six months for paediatric trials). Lay summaries must be provided for all trials. The summary must include results regardless of outcome, addressing the problem of non-publication of negative results.

Article 81 requires sponsors to provide a summary of results for all Phase I trials within 15 years of the Regulation’s application. The EMA makes information publicly available, including the clinical study report upon request.

Safety Reporting

Title VII (Articles 41–48) establishes a streamlined safety reporting system. Adverse events and serious adverse events are reported through EudraVigilance, the EU pharmacovigilance database. The investigator must report serious adverse events to the sponsor immediately; the sponsor must submit suspected unexpected serious adverse reactions (SUSARs) within seven (fatal) or 15 (non-fatal) days.

Lifecycle Management

The Regulation introduces a single assessment procedure for substantial amendments (Article 16). Modifications to trial conduct that significantly affect participant safety, rights, or the reliability of results require prior authorisation through CTIS. The sponsor may implement the amendment without waiting for all Member States’ approval where the RMS assessment is favourable.

Enforcement and Penalties

Member States may suspend or terminate a clinical trial where conditions are no longer met, and must notify the EMA. Penalties for non-compliance must be effective, proportionate, and dissuasive.